Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Baxter reports positive data for haemophilia therapy

Baxter reports positive data for haemophilia therapy

9th January 2013

Baxter has reported positive trial data supporting the potential benefits of its haemophilia therapy FEIBA NF in a new indication.

Pivotal phase III study results demonstrated the efficacy and safety of routine prophylaxis compared to on-demand treatment of FEIBA NF in patients with haemophilia A or B and inhibitors.

This is a potentially important discovery as around one-third of people with haemophilia develop an inhibitor to a product used to treat or prevent bleeding episodes, making treatment more challenging and increasing the risk of complications such as joint damage.

The data will form the basis of a  biologics license application to be filed with the US Food and Drug Administration in the first quarter of 2013.

Professor Hartmut Ehrlich, vice-president of global research and development in Baxter's BioScience business, said: "The FEIBA NF prophylaxis study demonstrates Baxter's dedication to providing treatment options to the haemophilia community, including effective inhibitor management."

This comes after the company announced it will also be commencing a phase II/III study of the investigational haemophilia A treatment BAX 855 during the current quarter.ADNFCR-8000103-ID-801519045-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.